169 related articles for article (PubMed ID: 12502672)
1. Optimal dose of candesartan for renoprotection in type 2 diabetic patients with nephropathy: a double-blind randomized cross-over study.
Rossing K; Christensen PK; Hansen BV; Carstensen B; Parving HH
Diabetes Care; 2003 Jan; 26(1):150-5. PubMed ID: 12502672
[TBL] [Abstract][Full Text] [Related]
2. Renoprotective effects of adding angiotensin II receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy: a randomized double-blind crossover trial.
Rossing K; Jacobsen P; Pietraszek L; Parving HH
Diabetes Care; 2003 Aug; 26(8):2268-74. PubMed ID: 12882847
[TBL] [Abstract][Full Text] [Related]
3. Dual blockade of the renin-angiotensin system in diabetic nephropathy: a randomized double-blind crossover study.
Rossing K; Christensen PK; Jensen BR; Parving HH
Diabetes Care; 2002 Jan; 25(1):95-100. PubMed ID: 11772908
[TBL] [Abstract][Full Text] [Related]
4. Autoregulated glomerular filtration rate during candesartan treatment in hypertensive type 2 diabetic patients.
Christensen PK; Lund S; Parving HH
Kidney Int; 2001 Oct; 60(4):1435-42. PubMed ID: 11576357
[TBL] [Abstract][Full Text] [Related]
5. Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria.
Rossing K; Schjoedt KJ; Jensen BR; Boomsma F; Parving HH
Kidney Int; 2005 Sep; 68(3):1190-8. PubMed ID: 16105050
[TBL] [Abstract][Full Text] [Related]
6. Optimal dose of losartan for renoprotection in diabetic nephropathy.
Andersen S; Rossing P; Juhl TR; Deinum J; Parving HH
Nephrol Dial Transplant; 2002 Aug; 17(8):1413-8. PubMed ID: 12147788
[TBL] [Abstract][Full Text] [Related]
7. Targeting albumin excretion rate in the treatment of the hypertensive diabetic patient with renal disease.
Krimholtz MJ; Karalliedde J; Thomas S; Bilous R; Viberti G
J Am Soc Nephrol; 2005 Mar; 16 Suppl 1():S42-7. PubMed ID: 15938033
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of Imarikiren in Patients with Type 2 Diabetes and Microalbuminuria: A Randomized, Controlled Trial.
Ito S; Kagawa T; Saiki T; Shimizu K; Kuroda S; Sano Y; Umeda Y
Clin J Am Soc Nephrol; 2019 Mar; 14(3):354-363. PubMed ID: 30755452
[TBL] [Abstract][Full Text] [Related]
9. Optimal dose of lisinopril for renoprotection in type 1 diabetic patients with diabetic nephropathy: a randomised crossover trial.
Schjoedt KJ; Astrup AS; Persson F; Frandsen E; Boomsma F; Rossing K; Tarnow L; Rossing P; Parving HH
Diabetologia; 2009 Jan; 52(1):46-9. PubMed ID: 18974967
[TBL] [Abstract][Full Text] [Related]
10. Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study.
Rossing K; Schjoedt KJ; Smidt UM; Boomsma F; Parving HH
Diabetes Care; 2005 Sep; 28(9):2106-12. PubMed ID: 16123474
[TBL] [Abstract][Full Text] [Related]
11. Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy.
Jacobsen P; Andersen S; Rossing K; Jensen BR; Parving HH
Kidney Int; 2003 May; 63(5):1874-80. PubMed ID: 12675866
[TBL] [Abstract][Full Text] [Related]
12. Additive effect of ACE inhibition and angiotensin II receptor blockade in type I diabetic patients with diabetic nephropathy.
Jacobsen P; Andersen S; Jensen BR; Parving HH
J Am Soc Nephrol; 2003 Apr; 14(4):992-9. PubMed ID: 12660333
[TBL] [Abstract][Full Text] [Related]
13. Effect of low-dose dual blockade of renin-angiotensin system on urinary TGF-beta in type 2 diabetic patients with advanced kidney disease.
Song JH; Cha SH; Lee HJ; Lee SW; Park GH; Lee SW; Kim MJ
Nephrol Dial Transplant; 2006 Mar; 21(3):683-9. PubMed ID: 16330466
[TBL] [Abstract][Full Text] [Related]
14. Differences between nisoldipine and lisinopril on glomerular filtration rates and albuminuria in hypertensive IDDM patients with diabetic nephropathy during the first year of treatment.
Rossing P; Tarnow L; Boelskifte S; Jensen BR; Nielsen FS; Parving HH
Diabetes; 1997 Mar; 46(3):481-7. PubMed ID: 9032106
[TBL] [Abstract][Full Text] [Related]
15. Combination of half doses of angiotensin type 1 receptor antagonist and angiotensin-converting enzyme inhibitor in diabetic nephropathy.
Fujisawa T; Ikegami H; Ono M; Nishino M; Noso S; Kawabata Y; Ogihara T
Am J Hypertens; 2005 Jan; 18(1):13-7. PubMed ID: 15691611
[TBL] [Abstract][Full Text] [Related]
16. A comparison of the efficacy and duration of action of candesartan cilexetil and losartan as assessed by clinic and ambulatory blood pressure after a missed dose, in truly hypertensive patients: a placebo-controlled, forced titration study. Candesartan/Losartan study investigators.
Lacourcière Y; Asmar R
Am J Hypertens; 1999 Dec; 12(12 Pt 1-2):1181-7. PubMed ID: 10619580
[TBL] [Abstract][Full Text] [Related]
17. Effects of the angiotensin II type 1 receptor antagonist candesartan, compared with angiotensin-converting enzyme inhibitors, on the urinary excretion of albumin and type IV collagen in patients with diabetic nephropathy.
Sato A; Tabata M; Hayashi K; Saruta T
Clin Exp Nephrol; 2003 Sep; 7(3):215-20. PubMed ID: 14586718
[TBL] [Abstract][Full Text] [Related]
18. Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials.
Bilous R; Chaturvedi N; Sjølie AK; Fuller J; Klein R; Orchard T; Porta M; Parving HH
Ann Intern Med; 2009 Jul; 151(1):11-20, W3-4. PubMed ID: 19451554
[TBL] [Abstract][Full Text] [Related]
19. Candesartan cilexetil, a new generation angiotensin II antagonist, provides dose dependent antihypertensive effect.
Elmfeldt D; George M; Hübner R; Olofsson B
J Hum Hypertens; 1997 Sep; 11 Suppl 2():S49-53. PubMed ID: 9331007
[TBL] [Abstract][Full Text] [Related]
20. Reduction of proteinuria; combined effects of receptor blockade and low dose angiotensin-converting enzyme inhibition.
Berger ED; Bader BD; Ebert C; Risler T; Erley CM
J Hypertens; 2002 Apr; 20(4):739-43. PubMed ID: 11910311
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
